Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)
NCT ID: NCT04222374
Last Updated: 2020-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2019-12-10
2020-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Dr. Mark PURDUE and Dr. Stephen CAHNOCK (Department of Epidemiology of Cancer and Genetics, NCI) propose to expand their genome-wide association study (Expanded GWAS) by genotyping approximately 10,000 additional cases of kidney cancer patients, in collaboration with US institutions, South-American and European.
This study describes the participation of the French Kidney Cancer Research Network (UroCCR) in the Expanded GWAS research, under the coordination of Professor BERNHARD (Bordeaux University Hospital).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma
NCT03414827
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
NCT00757614
Prostate Cancer Genomic Heterogeneity
NCT02022371
Genetic Investigation of Cancer Predisposition
NCT04620278
A Genotype-Phenotype Urothelial Cancer Registry
NCT00902590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The participation of the French UroCCR network consists in completing the bio-collection of the UroCCR cohort by preserving constitutional DNA and to provide DNA samples to the US NCI team.
This will increase the number of samples for meta-analysis and contribute to better identify clear cell kidney cancer susceptibility loci.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intervention in the UroCCR sites
1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)
2. DNA extraction:
* For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:
* 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,
* 1 aliquot for the UroCCR biobank.
* For patients from other UroCCR centers, only 1 aliquot will be constituted:
* 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.
3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux.
Intervention in the CRB of Bordeaux University Hospital
1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.
2. Overall packing of GWAS samples for shipment to the NCI.
3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study.
Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital
Transfer of the data associated with the samples to the NCI.
Subsequent intervention at the NCI (for information)
1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.
2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed cases of renal cell carcinoma (any RCC histology) of European or African origin,
* Patients included in the UroCCR study,
* Free, informed, written and signed consent by the participant and the investigator (at the latest on the day of inclusion and before any investigation required by the research) for specific blood collection for the purpose of DNA extraction,
* Programmed or ongoing management for kidney tumor,
* Constitutional DNA available (whole blood) for selected cases,
* Affiliated person or beneficiary of a social security scheme.
Exclusion Criteria
* Refusal of consent or participation.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire de Bordeaux
Talence, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2019/20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.